A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Clinical trial NCT06890338 · RECRUITING

Trial details

NCT number: NCT06890338
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Neoadjuvant

Start date: 2025-11-21
Primary completion: 2030-02-01
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.